Portal de Periódicos da CAPES

Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis

1996; Wiley; Volume: 61; Issue: 2 Linguagem: Inglês

10.1002/(sici)1096-9098(199602)61

1096-9098

Bradley F. Schwartz, Richard Auman, Samuel J. Peretsman, Judd W. Moul, George E. Deshon, Javier Hernández, Thomas A. Rozanski, J. Brantley Thrasher,

Urologic and reproductive health conditions

Journal of Surgical OncologyVolume 61, Issue 2 p. 131-133 Prognostic value of BHCG and local tumor invasion in stage I seminoma of the testis Bradley F. Schwartz DO, Corresponding Author Bradley F. Schwartz DO Department of Urology, Madigan Army Medical Center, Tacoma, WashingtonDepartment of Urology, Madigan Army Medical Center, Tacoma, WA 98431-5000Search for more papers by this authorRichard Auman MD, Richard Auman MD Department of Urology, Portsmouth Naval Hospital, Portsmouth, VirginiaSearch for more papers by this authorSamuel J. Peretsman MD, Samuel J. Peretsman MD Department of Urology, Wilfrod Hall Medical Center, San Antonio, TexasSearch for more papers by this authorJudd W. Moul MD, Judd W. Moul MD Department of Urology, Walter Reed Medical Center, Washington, D.C.Search for more papers by this authorGeorge E. Deshon MD, George E. Deshon MD Department of Urology, Tripler Army Medical Center, Honolulu, HawaiiSearch for more papers by this authorJavier Hernandez MD, Javier Hernandez MD Department of Urology, Brooke Army Medical Center, San Antonio, TexasSearch for more papers by this authorThomas A. Rozanski MD, Thomas A. Rozanski MD Department of Urology, Brooke Army Medical Center, San Antonio, TexasSearch for more papers by this authorJ. Brantley Thrasher MD, J. Brantley Thrasher MD Department of Urology, Madigan Army Medical Center, Tacoma, WashingtonSearch for more papers by this author Bradley F. Schwartz DO, Corresponding Author Bradley F. Schwartz DO Department of Urology, Madigan Army Medical Center, Tacoma, WashingtonDepartment of Urology, Madigan Army Medical Center, Tacoma, WA 98431-5000Search for more papers by this authorRichard Auman MD, Richard Auman MD Department of Urology, Portsmouth Naval Hospital, Portsmouth, VirginiaSearch for more papers by this authorSamuel J. Peretsman MD, Samuel J. Peretsman MD Department of Urology, Wilfrod Hall Medical Center, San Antonio, TexasSearch for more papers by this authorJudd W. Moul MD, Judd W. Moul MD Department of Urology, Walter Reed Medical Center, Washington, D.C.Search for more papers by this authorGeorge E. Deshon MD, George E. Deshon MD Department of Urology, Tripler Army Medical Center, Honolulu, HawaiiSearch for more papers by this authorJavier Hernandez MD, Javier Hernandez MD Department of Urology, Brooke Army Medical Center, San Antonio, TexasSearch for more papers by this authorThomas A. Rozanski MD, Thomas A. Rozanski MD Department of Urology, Brooke Army Medical Center, San Antonio, TexasSearch for more papers by this authorJ. Brantley Thrasher MD, J. Brantley Thrasher MD Department of Urology, Madigan Army Medical Center, Tacoma, WashingtonSearch for more papers by this author First published: February 1996 https://doi.org/10.1002/(SICI)1096-9098(199602)61:2 3.0.CO;2-DCitations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Approximately 10–15% of patients with stage I pure seminoma of the testis have an elevated preorchiectomy serum beta human chorionic gonadotropin level [1–4]. The prognostic significance of this elevation is unknown. We performed a multi-institutional retrospective review of 332 men with stage I pure seminoma of the testis and evaluated the prognostic significance of this elevation and the prognostic value of local invasion of the primary tumor. Twenty-five of 191 evaluable patients (13%) had elevated preorchiectomy beta human chorionic gonadotropin. All normalized postoperatively and are alive without evidence of disease with a median follow-up of 50 months (range 1–124 mo). Of 191 patients, 190 (99.5%) are alive and free of disease. One patient underwent salvage chemotherapy for a chest recurrence, and he is alive and free of disease at 72 months. We conclude that elevated preorchiectomy serum beta human chorionic gonadotropin level and local invasion of the primary tumor do not portend a poor prognosis in patients with clinical stage I pure seminoma of the testis. (This is a US Government work and, as such is in the public domain in the United States of America.) © 1996 Wiley-Liss, Inc. References 1 Mirimanoff RO, Sinzing M, Kruger M, et al.: Prognosis of human chorionic gonadotropin-producing seminoma treated by postoperative radiotherapy. Int J Rad One Bio Phys 27: 17–23, 1993. 10.1016/0360-3016(93)90416-S CASPubMedWeb of Science®Google Scholar 2 Dieckman KP, Due W, Bauer HU: Seminoma testis with elevated serum Beta HCG—a category of germ-cell cancer between seminoma and nonseminoma. Int Urol Neph 21(2): 175–184, 1989. 10.1007/BF02550806 CASGoogle Scholar 3 Butcher DN, Gregory WM, Gunter PA, et al.: The biological and clinical significance of HCG-containing cells in seminoma. Br J Cancer 51(4): 473–478, 1985. 10.1038/bjc.1985.68 CASPubMedWeb of Science®Google Scholar 4 Javadpour N, McLntke KR, Waldmann TA: Human chorionic gonadotropin (HCG) and alpha-fetoprotein (AFP) in sera and tumor cells of patients with testicular seminoma. Cancer 42: 2768–2772, 1978. 10.1002/1097-0142(197812)42:6 3.0.CO;2-Z CASPubMedWeb of Science®Google Scholar 5 Hoskin P, Dilly S, Easton D, et al.: Prognostic factors in stage I non-seminomatous germ-cell testicular tumors managed by orchiectomy and surveillance: Implications for adjuvant chemotherapy. J Clin Oncol 4(7): 1031–1036, 1986. CASPubMedWeb of Science®Google Scholar 6 Johnson DE, Bracken RB, Blight EM: Prognosis for pathologic stage I non-seminomatous germ cell tumors of the testis managed by retroperitoneal lymphadenectomy. J Urol 116: 63–65, 1976. 10.1016/S0022-5347(17)58676-0 CASPubMedWeb of Science®Google Scholar 7 Maier JG, Sulak MH: Radiation therapy in malignant testis tumors. Cancer 32: 1217–1226, 1973. 10.1002/1097-0142(197311)32:5 3.0.CO;2-Q CASPubMedWeb of Science®Google Scholar 8 Lange PH, Nochomovitz LE, Rosai J, et al.: Serum alpha-fetoprotein and human chorionic gonadotropin in patients with seminoma. J Urol 124: 472–478, 1980. 10.1016/S0022-5347(17)55500-7 CASPubMedWeb of Science®Google Scholar 9 Swartz DA, Johnson DE, Hussey DH: Should an elevated human chorionic gonadotropin liter alter therapy for seminoma? J Urol 131: 63–65, 1984. 10.1016/S0022-5347(17)50204-9 CASPubMedWeb of Science®Google Scholar 10 Scheiber K, Mikuz G, Frommhold H, Bartsch G: Human chorionic gonadotropin-positive seminoma: Is this a special type of seminoma with a poor prognosis? Prog Clin Biol Res 203: 97–104, 1985. CASPubMedGoogle Scholar 11 Mirimanoff RO, Shipley WU, Dosoretz DE, Meyer JE: Pure seminoma of the testis: The results of radiation therapy in patients with elevated human chorionic gonadotropin titers. J Urol 134: 1124–1126, 1985. 10.1016/S0022-5347(17)47653-1 CASPubMedWeb of Science®Google Scholar Citing Literature Volume61, Issue2February 1996Pages 131-133 ReferencesRelatedInformation